ThermoGenesis Holdings Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Chris Xu
Algemeen directeur
US$520.0k
Totale compensatie
Percentage CEO-salaris | 100.0% |
Dienstverband CEO | 8yrs |
Eigendom CEO | n/a |
Management gemiddelde ambtstermijn | geen gegevens |
Gemiddelde ambtstermijn bestuur | 8.7yrs |
Recente managementupdates
Recent updates
It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks
Apr 17ThermoGenesis reports Q2 results
Aug 11Is ThermoGenesis Holdings (NASDAQ:THMO) Using Too Much Debt?
Oct 20Is ThermoGenesis Holdings (NASDAQ:THMO) A Risky Investment?
May 31When Will ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Become Profitable?
Apr 06Here's Why ThermoGenesis Holdings (NASDAQ:THMO) Can Afford Some Debt
Feb 10Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?
Dec 15ThermoGenesis EPS misses by $0.27, misses on revenue
Nov 12Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$15m |
Dec 31 2023 | US$520k | US$520k | -US$18m |
Sep 30 2023 | n/a | n/a | -US$14m |
Jun 30 2023 | n/a | n/a | -US$14m |
Mar 31 2023 | n/a | n/a | -US$14m |
Dec 31 2022 | US$699k | US$519k | -US$11m |
Sep 30 2022 | n/a | n/a | -US$10m |
Jun 30 2022 | n/a | n/a | -US$9m |
Mar 31 2022 | n/a | n/a | -US$11m |
Dec 31 2021 | US$748k | US$500k | -US$11m |
Sep 30 2021 | n/a | n/a | -US$12m |
Jun 30 2021 | n/a | n/a | -US$12m |
Mar 31 2021 | n/a | n/a | -US$14m |
Dec 31 2020 | US$2m | US$505k | -US$16m |
Sep 30 2020 | n/a | n/a | -US$18m |
Jun 30 2020 | n/a | n/a | -US$17m |
Mar 31 2020 | n/a | n/a | -US$12m |
Dec 31 2019 | US$472k | US$472k | -US$9m |
Sep 30 2019 | n/a | n/a | -US$13m |
Jun 30 2019 | n/a | n/a | -US$13m |
Mar 31 2019 | n/a | n/a | -US$39m |
Dec 31 2018 | US$653k | US$460k | -US$40m |
Sep 30 2018 | n/a | n/a | -US$32m |
Jun 30 2018 | n/a | n/a | -US$32m |
Mar 31 2018 | n/a | n/a | -US$6m |
Dec 31 2017 | US$1m | US$216k | -US$6m |
Compensatie versus markt: De totale vergoeding ($USD 520.00K ) Chris } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 656.26K ).
Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Chris Xu (53 yo)
8yrs
Tenure
US$520,000
Compensatie
Dr. Xiaochun Xu, also known as Chris, M.B.A. Ph D., serves as Chief Executive Officer and Chairman at ImmuneCyte Life Sciences, Inc. Dr. Xu is the Founder, Chairman and Chief Executive Officer of Boyalife...
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Chairman of the Board & CEO | 8.7yrs | US$520.00k | geen gegevens | |
Member of Clinical & Scientific Advisory Board | 10.5yrs | geen gegevens | geen gegevens | |
Member of Clinical Advisory Board | 8.7yrs | geen gegevens | geen gegevens | |
Independent Director | 1.3yrs | US$10.00k | geen gegevens |
8.7yrs
Gemiddelde duur
Ervaren bestuur: De raad van bestuur van THMO wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.7 jaar).